All articles tagged with #plaque psoriasis
A 47-year-old woman with plaque psoriasis endures years of failed treatments and emotional distress until she joins a clinical trial for ICOTYDE, the first oral therapy approved for the condition. Her symptoms dramatically clear, transforming both her skin and self-confidence, and she urges others not to let disease define them.
A 47-year-old woman, Amber Dean, suffered years of physical and emotional torment from plaque psoriasis, enduring misdiagnoses and failed treatments until she joined a clinical trial for ICOTYDE, the first oral medication for the condition. She now reports full skin clearance and a renewed sense of self, calling the decision one of her best health choices and urging others not to be defined by the disease.
The FDA approved ICOTYDE (icotrokinra), the first oral peptide that selectively blocks the IL-23 receptor, for adults and adolescents 12+ weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In Phase 3 ICONIC trials, about 70% achieved IGA 0/1 and 55% reached PASI-90 by Week 16, with adverse events similar to placebo through Week 16 and no new safety signals through Week 52, suggesting a convenient once-daily option that could shift systemic treatment patterns. Johnson & Johnson notes patient support via ICOTYDE withMe and collaboration with Protagonist Therapeutics.
The U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx), developed by UCB, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes. Clinical trials showed that a high percentage of patients treated with bimekizumab achieved clear or almost clear skin, with some achieving complete clearance. Psoriasis affects over 7.5 million adults in the U.S., and the approval of bimekizumab provides a new treatment option for patients.